Indivior plc ( (INDV) ) has released its Q2 earnings. Here is a breakdown of the information Indivior plc presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Indivior PLC is a global pharmaceutical company dedicated to developing medicines for opioid use disorder (OUD), with a strong presence in over 30 countries and a focus on transforming OUD into a recognized and treated chronic disease.
In its second quarter of 2025, Indivior reported a total net revenue of $302 million, with SUBLOCADE net revenue reaching $209 million, marking a 9% increase year-over-year. The company has raised its financial guidance for the full year 2025, reflecting strong performance driven by SUBLOCADE’s growth and pricing stability in the U.S. market.
Key financial highlights include a 1% increase in total net revenue compared to the previous year, with U.S. SUBLOCADE net revenue up by 9%. The company also reported a gross margin of 83% and a net income of $18 million, a significant turnaround from a net loss in the previous year. Indivior has initiated the Indivior Action Agenda to drive operational momentum and simplify its organization, aiming for long-term growth and cash generation.
Strategic moves include the cancellation of its London Stock Exchange listing to focus on Nasdaq trading and the inclusion in the Russell Equity Indexes. Indivior also presented new data on SUBLOCADE’s effectiveness and published studies supporting its use during pregnancy and in reducing emergency department visits for OUD patients.
Looking ahead, Indivior is committed to achieving its revised financial guidance for 2025, with a focus on growing U.S. SUBLOCADE revenue and implementing organizational changes to position the company for future growth phases. The management remains optimistic about advancing to the next phase of its strategic agenda in 2026.